AdjuTec has recently signed a new patent (Hanox) from professor Pål Rongved, covering a product for treatment of multidrug resistant tuberculosis (TB-MDR). TB is the most critical pathogen on the WHO list and affects 10mill people world-wide per year, with the majority of patients living in South-East Asia. There is a concern with increasing resistance (TB-MDR), reaching more than 200.000 cases. The direct cost of treating a person with TB-MDR increases with severity of resistance, and range from $134.000-430.000 (CDC, 2014). The first new product for TB-MDR in 40 years (bedaquiline) was recently approved in the US, but carries a risk of disturbing side-effects. The Hanox patent was recently approved in the US and is pending in Europe. Adjutec is applying for public grants to accelerate the development of this asset.
“Strengthening the patent portfolio of AdjuTec is of high importance to attract public and private funding and generate more value for our shareholders. Adjutec is committed to accelerate development of APC148 but will have an opportunistic view on new opportunities that supports our strategy and comply with Company resources.” said Nicolaj Weiergang, AdjuTec Pharma Chairman of the Board.
About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
AMR is a global health and development threat. It requires urgent multi-sectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials are the main drivers in the development of drug-resistant pathogens. Lack of clean water and sanitation and inadequate infection prevention and control promotes the spread of microbes, some of which can be resistant to antimicrobial treatment. The cost of AMR to the economy is significant. In addition to death and disability, prolonged illness results in longer hospital stays at intensive care units and isolate wards. In addition, there is a need for more expensive medicines and financial challenges for those impacted. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.
About AdjuTec Pharma
AdjuTec Pharma is a Company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The Company technology offers a unique mechanism of action that inactivates bacterial defense enzymes and restores bacterial sensitivity to antibiotics. The Company lead product is APC148, a selective zinc chelator targeting bacteria metallo-ß-lactamase (MBL) enzymes. The technology is developed by Professor Pål Rongved and his group at Department of Pharmacy, University of Oslo. The Company is located at Oslo Cancer Cluster Innovation Park next to the Radium Hospital, Oslo.
For more information, please visit www.adjutecpharma.com
Please contact: info@adjutecpharma.com